招银国际发表研究报告指，药明生物(02269.HK) 去年收入按年增长9.6%，经调整利润按年增长9%，收入和利润增长均接近早前指引区间高位。非新冠收入按年增长 13.1%，显示出稳健的客户需求。管理层预计今年收入将增长12%至15%，持续经营收入按年增长17%至20%。该行预计，药明生物今年、明年及2027年收入按年增长14.4%、16.3%及17.5%，经调整归母净利润按年增长为16.3%、...
Source Link招银国际发表研究报告指，药明生物(02269.HK) 去年收入按年增长9.6%，经调整利润按年增长9%，收入和利润增长均接近早前指引区间高位。非新冠收入按年增长 13.1%，显示出稳健的客户需求。管理层预计今年收入将增长12%至15%，持续经营收入按年增长17%至20%。该行预计，药明生物今年、明年及2027年收入按年增长14.4%、16.3%及17.5%，经调整归母净利润按年增长为16.3%、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.